Home / Research / Publications / Multiomic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes
Trastuzumab deruxtecan-nxki (T-DXd) was approved on April 5, 2024, by the US Food and Drug Administration for adults with unresectable or metastatic human epidermal growth… […]
Durable Response in NTRK Fusion-Positive Advanced Salivary Gland Tumor: A Case Report
Abstract Introduction:NTRK fusions lead to the production of constitutively active TRK proteins, which drive oncogenesis in approximately 0.2% of cancers. However, these fusions occur more frequently… […]